End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.084 AUD | -1.18% | -5.62% | +42.37% |
Jun. 03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
May. 29 | Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.37% | 50.03M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+2.82% | 22.39B | |
-11.72% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- PER Stock
- News Percheron Therapeutics Limited
- Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%